Reference

Chronic heart rate reduction with ivabradine and prevention of atherosclerosis progression assessed using intravascular ultrasound

Chronic heart rate reduction with ivabradine and prevention of atherosclerosis progression assessed using intravascular ultrasound. Tardiff, J.-C.; Gregoire, J.; Lallier, P. L.; Joyal, M. (Department of Medicine, Montreal Heart Institute, Montreal, Can.). European Heart Journal Supplements, 5(Suppl. G), G46-G51 (English) 2003 Elsevier B.V. CODEN: EHJSFT. ISSN: 1520-765X. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Exptl. data have shown that redn. in atherosclerosis progression can be obtained through chronic heart rate redn. Heart rate is significantly correlated with the severity and progression of atherosclerosis on coronary angiog. in patients. Limitation of the progression of atherosclerosis may therefore become an important therapeutic target of the specific heart rate reducing agent ivabradine. The ability of intravascular ultrasound (IVUS) to assess plaque burden precisely makes it the ideal tool for a clin. trial of progression and regression of atherosclerosis. The present article provides an overview of the design and of some methodol. features of a clin. trial to assess the effects of ivabradine on the progression of coronary atherosclerosis, as assessed by IVUS.Except for chemicals metioned above, 155974-00-8 is also used. .

Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study

All Rights Reserved. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study. Fox, Kim; Ferrari, Roberto; Tendera, Michal; Steg, Philippe Gabriel; Ford, Ian (the Beautiful Steering Committee; Royal Brompton Hospital, London, UK). American Heart Journal, 152(5), 860-866 (English) 2006 Elsevier. CODEN: AHJOA2. ISSN: 0002-8703. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Background: Raised resting heart rate (HR) is assocd. with increased cardiovascular and total mortality. Ivabradine is a new specific HR-reducing agent, which has been shown to have antianginal and anti-ischemic properties in patients with stable angina. Because patients with coronary artery disease and left ventricular dysfunction are at high risk of cardiac events and death, we hypothesized that they could derive particular benefit from a specific HR-lowering agent such as ivabradine. Methods: BEAUTIFUL is a multicenter, randomized, international, double-blind placebo-controlled trial to evaluate the superiority of ivabradine over placebo in reducing cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction (ejection fraction ￡39%). The primary end point is the composite of cardiovascular mortality and hospital admission for acute myocardial infarction or new onset or worsening of heart failure. This event-driven study will randomize 9650 patients and continue until 950 primary end points have occurred, providing 90% power to detect a 19% redn.Several substances like 155974-00-8 may be metioned in this study. in relative risk. In approx. 660 centers, men and women aged 355 years if nondiabetic and 318 years if diabetic are randomized to placebo or oral ivabradine (5 mg twice daily for 2 wk then target dose of 7.5 mg twice daily). Follow-up is expected to last between 18 and 36 mo. Results: The first patient was randomized in Jan. 2005. Conclusion: BEAUTIFUL will be the first major outcome trial of a specific HR-reducing agent. The study results are expected in 2008. .